Want to join the conversation?
During 1Q16, the use of lab core data played a key role in winning a large Phase III oncology study which increased $LH's cumulative orders from use of lab core data to over $190MM. The company has begun to convert this backlog into revenue and remains on track to deliver $150MM in incremental revenue through 2018.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?